Biopharmaceutical News and Research

RSS

Kiadis Pharma to receive innovation credit from AgentschapNL to conduct Phase II study for ATIR

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it will receive an innovation credit of up to €3 million from AgentschapNL, a division of the Dutch Ministry of Economic Affairs, to support the Phase II clinical development of Kiadis Pharma's lead pipeline product, ATIR™

26 Jun 2013

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced that it has reached the targeted enrollment of 105 evaluable patients in its international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for soft tissue sarcoma.

25 Jun 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.

17 Jun 2013

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young Entrepreneur Of The Year® 2013 Award in the Life Sciences category in New Jersey. Dr. Nader was presented with the award at a special gala event on June 13 at the Hyatt Regency New Brunswick, New Jersey.

15 Jun 2013

NICE Appraisal Committee reconfirms clinical effectiveness of ILUVIEN

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence has issued a positive Appraisal Consultation Document on ILUVIEN for the treatment of pseudophakic patients with chronic diabetic macular edema considered insufficiently responsive to available therapies.

14 Jun 2013

Perfinity, Thermo Fisher Scientific sign co-marketing agreement for automated online biopharmaceutical analysis system

Perfinity Biosciences Inc. has announced the signing of an agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to co-market an automated protein sample preparation and analysis system.

From Thermo Fisher Scientific Inc. 13 Jun 2013

Medicago gets Health Canada clearance to initiate Phase II clinical trial for H5N1 vaccine

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").

11 Jun 2013

MHN, Auxilium Pharmaceuticals launch new health awareness program on Peyronie's disease

Men's Health Network and Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, have announced the launch of a new health awareness program called "Ask About the Curve" to provide information about Peyronie's disease and to help empower men to have meaningful discussions about their condition with their partner and their healthcare provider.

11 Jun 2013

GE Healthcare plans to invest $2 billion to develop innovative software for healthcare systems

GE Healthcare announced today its plans to invest $2 billion over the next five years to accelerate the development of innovative software for healthcare systems and applications.

11 Jun 2013

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.

10 Jun 2013

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Edge Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing life-saving hospital products for acute, fatal or debilitating conditions, announced today that the U.S. Food and Drug Administration has accepted the Company's Investigational New Drug application for EG-1962, a novel bio-absorbable nimodipine microparticle formulation.

10 Jun 2013

Diagnoplex secures 1.3 million Swiss francs from financing round

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm.

7 Jun 2013

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia.

6 Jun 2013

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine").

6 Jun 2013

New survey data reveal need for specialist nurse support in management of patients with heart failure

One year after the publication of the European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012, awareness amongst UK healthcare professionals varies dramatically.

6 Jun 2013

BioTools bridges the empirical: computational chemistry chasm with ComputeVOA

Chiral molecules, those “left/right” mirror image marvels of nature, determine much of our biology and, as a result, are of prime interest to biologists, organic chemists, and especially, the pharmaceutical industry.

4 Jun 2013

Zalicus advancing Z944 into further clinical development

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it is advancing Z944, its novel oral T-type calcium channel blocker, into further clinical development in the third quarter of 2013.

4 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients has received "Fast Track" designation from the US Food and Drug Administration.

3 Jun 2013

Biopharmaceutical News and Research

Kiadis Pharma to receive innovation credit from AgentschapNL to conduct Phase II study for ATIR

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

NICE Appraisal Committee reconfirms clinical effectiveness of ILUVIEN

Perfinity, Thermo Fisher Scientific sign co-marketing agreement for automated online biopharmaceutical analysis system

Medicago gets Health Canada clearance to initiate Phase II clinical trial for H5N1 vaccine

MHN, Auxilium Pharmaceuticals launch new health awareness program on Peyronie's disease

GE Healthcare plans to invest $2 billion to develop innovative software for healthcare systems

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Diagnoplex secures 1.3 million Swiss francs from financing round

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

New survey data reveal need for specialist nurse support in management of patients with heart failure

BioTools bridges the empirical: computational chemistry chasm with ComputeVOA

Zalicus advancing Z944 into further clinical development

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Event guide: 3rd EHS for Biopharma Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News